July 2 (Reuters) - Japanese merger and acquisition volumes fell 22 percent in the first half this year compared with the same period a year ago, totaling $64 billion, according to Thomson Reuters data.
The pharmaceuticals sector has been the most active for Japanese M&A, thanks to Takeda Pharmaceutical Co Ltd's $8.1 billion deal for U.S.-based Millennium Pharmaceuticals and Daiichi Sankyo's $4.6 billion takeover of India's Ranbaxy Laboratories Ltd.
Nomura topped the league table for financial advisers on Japanese M&A deals in the first half. It was also the top adviser in the same period last year and for all of 2007.
Below is a list of the top 5 M&A advisers by value.
For a related story, click on
Rank for Adviser Value all of 2007 ------------------------------------------------------ Nomura $20.9 bln 1 UBS $12.9 bln 13 Goldman Sachs $10.8 bln 5 Mitsubishi UFJ $8.5 bln 6 JPMorgan $5.2 bln 9
(Reporting by Tony Munroe)
Provided by Reuters
© Reuters 2008 All rights reserved
If you find an article which you feel violate your rights or the rights of others, please notify us immediately.
Share this story:Post your Comment Email Print Bookmark this page
How to end its power shortage
The following is a series of measures Beijing has taken to reduce...
What Studies You Pay for
Researchers Look at Random Sex, Beauty, and the Obvious...
Digg
Reddit
Mixx it
Facebook
